Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor

Published:2013-01-11 Issue:3 Volume:6 Page:355-363
ISSN:1937-5387
Container-title:Journal of Cardiovascular Translational Research
language:en
Short-container-title:J. of Cardiovasc. Trans. Res.

Author:

Bartunek Jozef,Barbato Emanuele,Heyndrickx Guy,Vanderheyden Marc,Wijns William,Holz Josefin-Beate

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Cardiology and Cardiovascular Medicine,Pharmaceutical Science,Genetics,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12265-012-9435-y.pdf

Reference37 articles.

1. Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., et al. (2012). Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation, 125(1), 2–220.

2. Muller, O., Hamilos, M., Bartunek, J., Ulrichts, H., Mangiacapra, F., Holz, J. B., et al. (2010). Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary in- tervention. The American Journal of Cardiology, 105(3), 333–8.

3. Bhatt, D. L., & Topol, E. J. (2003). Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews. Drug Discovery, 2(1), 15–28.

4. Jackson, S. P., & Schoenwaelder, S. M. (2003). Antiplatelet therapy: in search of the ‘magic bullet’. Nature Reviews. Drug Discovery, 2(10), 775–789.

5. Kumar, A., & Cannon, C. P. (2009). Acute coronary syndromes: diagnosis and management, part II. Mayo Clinic proceedings. Mayo Clinic, 84(11), 1021–36.

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining poly-epitope MoonTags and labeled nanobodies for signal amplification in cell-specific PET imaging in vivo;Nuclear Medicine and Biology;2024-09

2. Single-domain antibodies as therapeutics for solid tumor treatment;Acta Pharmaceutica Sinica B;2024-07

3. Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis;Blood Coagulation & Fibrinolysis;2024-06-10

4. Prospects for the computational humanization of antibodies and nanobodies;Frontiers in Immunology;2024-05-15

5. Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies;Cancer Cell International;2024-02-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3